

Call for Abstracts Frequently Asked Questions (FAQs)

Q: What is the character/word count?

A: 3,000 characters including spaces.

Q: Does the character/word count include title, author names, affiliations, etc.?

A: No, just the abstract body is counted toward this count.

Q: During submission if you choose oral presentation opposed to poster and your abstract is not selected for oral will it still be considered for poster presentation?

A: Yes, if you indicate you are open to having your abstract considered for poster presentation.

Q: Are tables allowed? Is there a limit to how many you can include in your abstract? Do they count towards the character limit?

A: Tables are not allowed as part of the abstract submission.

Q: Are figures allowed? Is there a limit to how many you can include in your abstract? Do they count towards the character limit?

A: Figures are not allowed as part of the abstract submission.

Q: Is there an author limit?

A: Yes, 25 co-authors.

Q: Is there a title character limit?

A: Yes, 200 characters.

Q: Are encore abstracts permitted?

A: Yes, although new data is encouraged, scoring will depend on expanding on what was presented at other meetings.

Q: Where are accepted abstracts published?

A: Abstracts will be published in a supplement of the *Clinical Lymphoma, Myeloma, & Leukemia* Journal.

Q: Are disclosures required?

A: Yes, this information will be collected upon abstract acceptance.

Q: Are Trials in Progress (TiP) allowed?

A: Yes, if tentative, data-based conclusions are stated in the abstract.

Q: Is a COI form required for each author as part of the submission process?

A: No, COI/disclosure forms will only be required for oral abstracts, upon acceptance from the presenting author.



Q: If I submit an abstract as a certain submission type, will it be accepted as that type?

A: The Program Committee may accept the abstract as a different type than what was originally submitted. This is usually due to the number of abstracts submitted in each category and how the information will best be presented.

Q: How do I submit an abstract?

A: Abstracts are submitted online through the abstract submission site. Abstracts must be submitted by the deadline of May 31, 2026, at 11:59 pm EST. Late-breaking abstracts will be accepted from July 6 – August 10, 2026, at 11:59 EST.

Q: How do I submit an abstract for the Nursing and Allied Health Symposium?

A: Nursing and Allied Health abstracts are submitted online through the abstract submission site. Please select "Nursing and Allied Health" for both the Presentation Format and Abstract Track. Abstracts must be submitted by the deadline of May 31, 2026, at 11:59 pm EST.

Q: How many presenting authors may I have?

A: Only one presenter per accepted abstract is permitted.

Q: What responsibilities does the Presenting Author have?

A: The presenting author has the following responsibility if the abstract is accepted:

- Present the abstract as scheduled.
- Ensure that all required financial and non-financial relationship disclosures have been submitted. Disclosure of financial relationships with commercial entities is required for the presenting author and his/her spouse and institution (oral abstract presenters only).
- Verbally announce disclosures prior to the presentation.
- Log in to the abstract submission system to confirm acceptance of the presentation and review the presentation guidelines.
- Prepare all abstract presentation materials in English, the official language of the IMS Annual Meeting.
- Register for the 23rd IMS Annual Meeting (note, presenting authors are responsible for all registration fees and personal expenses related to the meeting).
- Presentation date and time assignments will be communicated in mid to late August. Presenters are expected to be available for the full duration of the IMS Annual Meeting, as abstract sessions occur Wednesday through Saturday, with many oral presentations scheduled for Saturday. Date or time change requests cannot be accommodated.

Q: What information do I need about my other authors?

A: You will need the full name, email address, institution, and location (city, state and country) for all authors.



23rd Annual MEETING & EXPOSITION

September 23-26, 2026 • Glasgow, Scotland



Q: May I submit more than one abstract?

A: Yes, there is no limit to the number of abstracts that you may submit. Authors who submit multiple abstracts should be prepared to plan for alternative presenters in case more than one abstract is accepted and presentation times overlap.

Q: Will I receive a confirmation email once I submit an abstract?

A: Yes, you will receive a confirmation email once the submission has been finalized. It will be sent from imsabstracts@spargoinc.com.

Q: When will I receive notification if my abstract was accepted or declined for presentation?

A: Abstract notifications will be emailed in Early July 2026. Late-breaking abstract notifications will be issued by Mid-August 2026.

Q: If selected, what day will I present?

A: Presentation date and time assignments will be sent in mid to late August. Abstract presenters are expected to be available for the full duration of the IMS Annual Meeting, as abstract sessions run from Wednesday through Saturday with many oral presentations scheduled for Saturday. Date changes/requests are not permitted.

Q: How are the abstracts reviewed?

A: All abstracts will be blinded and peer reviewed by the Program Committee and invited reviewers. The reviewers assign scores based on topic, relevance, innovation, quality of material, interest to IMS attendees, and available space. Abstracts are selected based on their aggregate score and slotted into sessions accordingly. Note that the Program Committee may change the abstract type, if accepted.

Q: Will IMS accept late abstracts?

A: Abstracts must be submitted by the deadline of May 31, 2026, at 11:59 p.m. EST. Late-Breaking Abstracts are open from July 6 – August 10, 2026, at 11:59 pm EST. The IMS organizers will not accept late submissions for abstracts during the standard period or late-breaking period.

Q: Can I make changes to the abstract after it has been finalized?

A: You may make changes to the abstract before the submission deadline. You will be required to re-finalize the abstract. Only finalized abstracts will be reviewed. No changes are permitted after the abstract deadline, other than the presenter, if accepted.

Q: May I change the presenter after my abstract is accepted?

A: You may change the presenter after an abstract is accepted by emailing imsabstracts@spargoinc.com. The new presenter must be an existing co-author on the abstract.

Q: How long do I have to withdraw my abstract?

A: Abstracts submitted by May 31, 2026 may be withdrawn up to July 6, 2026 11:59 pm EST. Withdrawals after this date, must be emailed to imsabstracts@spargoinc.com.



Q: Are there any discounts for presenters to attend the IMS Annual Meeting?

A: Individuals who submit an abstract for consideration and reside in a lower/middle income country will receive a \$100 discount off the registration fee. Check your eligibility [here](#).

Q: Who retains the copyright for accepted abstracts?

A: IMS holds the copyright for all accepted abstracts.